<産業資料/調査レポートの題名> 2022年7月15日

抗線溶薬の世界市場:疾患別(婦人科、遺伝性血管浮腫、線溶反応試験、手術、その他)、エンドユーザー別(病院&クリニック、外来手術センター、医療専門プロセス)


◆英文タイトル:Antifibrinolytic Drugs Market by Indication (Gynecology, Hereditary Angiedema, Fibrinolytic Response Testing, Surgeries, and Others) and End user (Hospitals & Clinics, Ambulatory Surgical Centers, and Healthcare Specialty Process): Global Opportunity Analysis and Industry Forecast, 2019–2026

Chapter 1: Introduction

1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.4. Research Methodology

1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models

Chapter 2: Executive Summary

2.1. Key Findings of The Study
2.2. Cxo Perspective

Chapter 3: Market Overview

3.1. Market Definition And Scope
3.2. Key Findings

3.2.1. Top Investment Pockets

3.3. Porter’S Five Forces Analysis

3.3.1. Moderate Bargaining Power of Buyers
3.3.2. Low Bargaining Power of Suppliers
3.3.3. Moderate Threat of Substitutes
3.3.4. Low Threat of New Entrants
3.3.5. Moderate Competitive Rivalry

3.4. Top Player Positioning
3.5. Market Dynamics

3.5.1. Drivers

3.5.1.1. Surge In Severe Road Accidents
3.5.1.2. Significant Increase In Surgical Procedures

3.5.2. Restraint

3.5.2.1. High Cost of These Drugs

3.5.3. Opportunity

3.5.3.1. Various Growth Opportunities In Emerging Economies

Chapter 4: Antifibrinolytic Drugs Market, By Indication

4.1. Overview

4.1.1. Market Size And Forecast

4.2. Gynecology

4.2.1. Key Market Trends And Opportunities
4.2.2. Market Size And Forecast
4.2.3. Market Share Analysis, By Country

4.3. Hereditary Angioedema

4.3.1. Key Market Trends And Growth Opportunities
4.3.2. Market Size And Forecast
4.3.3. Market Share Analysis, By Country

4.4. Fibrinolytic Response Testing

4.4.1. Key Market Trends And Opportunities
4.4.2. Market Size And Forecast
4.4.3. Market Share Analysis, By Country

4.5. Surgeries

4.5.1. Key Market Trends And Opportunities
4.5.2. Market Size And Forecast
4.5.3. Market Share Analysis, By Country

4.6. Others

4.6.1. Key Market Trends And Opportunities
4.6.2. Market Size And Forecast
4.6.3. Market Share Analysis, By Country

Chapter 5: Antifibrinolytic Drugs Market, By End User

5.1. Overview

5.1.1. Market Size And Forecast

5.2. Hospitals

5.2.1. Market Size And Forecast
5.2.2. Market Share Analysis, By Country

5.3. Ambulatory Surgery Centers

5.3.1. Market Size And Forecast
5.3.2. Market Share Analysis, By Country

5.4. Trauma Centers

5.4.1. Market Size And Forecast
5.4.2. Market Share Analysis, By Country

Chapter 6: Antifibrinolytic Drugs Market, By Region

6.1. Overview

6.1.1. Market Size And Forecast

6.2. North America

6.2.1. Key Market Trends And Opportunities
6.2.2. Market Size And Forecast, By Country
6.2.3. Market Size And Forecast, By Indication
6.2.4. Market Size And Forecast, By End User
6.2.5. U.S.

6.2.5.1. U.S. Market Size And Forecast, By Indication
6.2.5.2. U.S. Market Size And Forecast, By End User

6.2.6. Canada

6.2.6.1. Canada Market Size And Forecast, By Indication
6.2.6.2. Canada Market Size And Forecast, By End User

6.2.7. Mexico

6.2.7.1. Mexico Market Size And Forecast, By Indication
6.2.7.2. Mexico Market Size And Forecast, By End User

6.3. Europe

6.3.1. Key Growth Factors And Opportunities
6.3.2. Market Size And Forecast, By Country
6.3.3. Market Size And Forecast, By Indication
6.3.4. Market Size And Forecast, By End User
6.3.5. Germany

6.3.5.1. Germany Market Size And Forecast, By Indication
6.3.5.2. Germany Market Size And Forecast, By End User

6.3.6. France

6.3.6.1. France Market Size And Forecast, By Indication
6.3.6.2. France Market Size And Forecast, By End User

6.3.7. Uk

6.3.7.1. Uk Market Size And Forecast, By Indication
6.3.7.2. Uk Market Size And Forecast, By End User

6.3.8. Italy

6.3.8.1. Italy Market Size And Forecast, By Indication
6.3.8.2. Italy Market Size And Forecast, By End User

6.3.9. Rest of Europe

6.3.9.1. Rest of Europe Market Size And Forecast, By Indication
6.3.9.2. Rest of Europe Market Size And Forecast, By End User

6.4. Asia-Pacific

6.4.1. Key Growth Factors And Opportunities.
6.4.2. Market Size And Forecast, By Country
6.4.3. Market Size And Forecast, By Indication
6.4.4. Market Size And Forecast, By End User
6.4.5. Japan

6.4.5.1. Japan Market Size And Forecast, By Indication
6.4.5.2. Japan Market Size And Forecast, By End User

6.4.6. China

6.4.6.1. China Market Size And Forecast, By Indication
6.4.6.2. China Market Size And Forecast, By End User

6.4.7. India

6.4.7.1. India Market Size And Forecast, By Indication
6.4.7.2. India Market Size And Forecast, By End User

6.4.8. Rest of Asia-Pacific

6.4.8.1. Rest of Asia-Pacific Market Size And Forecast, By Indication
6.4.8.2. Rest of Asia – Pacific Market Size And Forecast, By End User

6.5. Lamea

6.5.1. Key Growth Factors And Opportunities
6.5.2. Market Size And Forecast, By Country
6.5.3. Market Size And Forecast, By Indication
6.5.4. Market Size And Forecast, By End User
6.5.5. Brazil

6.5.5.1. Brazil Market Size And Forecast, By Indication
6.5.5.2. Brazil Market Size And Forecast, By End User

6.5.6. Saudi Arabia

6.5.6.1. Saudi Arabia Market Size And Forecast, By Indication
6.5.6.2. Saudi Arabia Market Size And Forecast, By End User

6.5.7. South Africa

6.5.7.1. South Africa Market Size And Forecast, By Indication
6.5.7.2. South Africa Market Size And Forecast, By End User

6.5.8. Rest of Lamea

6.5.8.1. Rest of Lamea Market Size And Forecast, By Indication
6.5.8.2. Rest of Lamea Market Size And Forecast, By End User

Chapter 7: Company Profiles

7.1. Akorn Inc.

7.1.1. Company Overview
7.1.2. Company Snapshot
7.1.3. Operating Business Segments
7.1.4. Product Portfolio
7.1.5. Business Performance

7.2. Aurobindo Pharma Limited

7.2.1. Company Overview
7.2.2. Company Snapshot
7.2.3. Operating Business Segments
7.2.4. Product Portfolio
7.2.5. Business Performance

7.3. Bayer Ag

7.3.1. Company Overview
7.3.2. Company Snapshot
7.3.3. Operating Business Segments
7.3.4. Product Portfolio
7.3.5. Business Performance

7.4. Ferring Holding Sa

7.4.1. Company Overview
7.4.2. Company Snapshot
7.4.3. Operating Business Segments
7.4.4. Product Portfolio
7.4.5. Business Performance

7.5. Mylan N.V.

7.5.1. Company Overview
7.5.2. Company Snapshot
7.5.3. Operating Business Segments
7.5.4. Product Portfolio
7.5.5. Business Performance

7.6. Novartis International Ag (Sandoz)

7.6.1. Company Overview
7.6.2. Company Snapshot
7.6.3. Operating Business Segments
7.6.4. Product Portfolio
7.6.5. Business Performance

7.7. Pfizer Inc.

7.7.1. Company Overview
7.7.2. Company Snapshot
7.7.3. Operating Business Segments
7.7.4. Product Portfolio
7.7.5. Business Performance

7.8. Sanofi S.A.

7.8.1. Company Overview
7.8.2. Company Snapshot
7.8.3. Operating Business Segments
7.8.4. Product Portfolio
7.8.5. Business Performance

7.9. Takeda Pharmaceutical Company Limited

7.9.1. Company Overview
7.9.2. Company Snapshot
7.9.3. Operating Business Segments
7.9.4. Product Portfolio
7.9.5. Business Performance

7.10. Vitruvias Therapeutics Inc.

7.10.1. Company Overview
7.10.2. Company Snapshot
7.10.3. Operating Business Segments
7.10.4. Product Portfolio
7.10.5. Business Performance
7.10.1. Key Strategic Moves And Developments


LINEで送る
Share on LinkedIn
このエントリーをはてなブックマークに追加
Bookmark this on BuzzURL
Bookmark this on Yahoo Bookmark